Functional alterations in the central and the autonomic nervous system (i.e. depressions, decrease of the parasympathetic activity) have been described previously
in patients with inflammatory bowel diseases (IBD). The cholinergic anti-inflammatory
pathway is an efferent vagus nerve-(VN) based mechanism that regulates immune responses
and cytokine production through α7nicotinic-acetylcholinereceptor (α7nAChR) signaling.
Over the last 10 years, it has been described that the VN plays a tonic inhibitory role on inflammation
and that pre-existing depression increases the development of experimental colitis
via a deactivation of the VN. Tricyclic antidepressants prevent this deleterious effect.
Moreover, electrical stimulation of the VN diminishes the production of inflammatory
cytokines in colitis and endotoxemia. Despite its clinical implications, the precise
physiological mechanisms contributing to the anti-inflammatory potential of the VN,
remains unknown. Acetylcholine (Ach) is the principal neurotransmitter of the VN and
previous studies analyzed the potential of cholinergic agonist to prevent TNF-α production
in peritoneal macrophages, suggesting a direct link between the VN and the antigen
presenting cell (APC)s. Recently, new data established the spleen as a key element
in this anti-inflammatory effect, postulating that the VN stimulation induces Ach
released by T cells, which inhibits cytokine production through the α7nAchR located
on macrophages and splenocytes. Therefore, it is very likely other type of APCs, like
dendritic cells (DC), play an important role in immune activation. Recent data demonstrated
that pharmacological central cholinergic activation induced by the acetylcholinesterase
inhibitor galantamine or a muscarinic acetylcholine receptor agonist treatments result
in reduced mucosal inflammation associated with decreased pro-inflammatory cytokine
secretion by splenic dendritic cells, mediated by α7nAChR signaling. Identification
of the cellular mechanism underlying the protective role of VN may lead to novel therapeutic
targets in the context of intestinal inflammation.
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Autonomic Neuroscience: Basic and ClinicalAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
Article info
Publication history
Received:
May 15,
2013
Identification
Copyright
© 2013 Published by Elsevier Inc.